American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2004
Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Warren Daniel S, Zachary Andrea A, Sonnenday Christopher J, King Karen E, Cooper Matthew, Ratner Lloyd E, Shirey R Sue, Haas Mark, Leffell Mary S, Montgomery Robert A
Аннотация
ABO incompatibility and human leukocyte antigen (HLA) sensitization remain the two largest barriers to optimal utilization of kidneys from live donors. Here we describe the first successful transplantation of patients who were both ABO incompatible and crossmatch positive with their only available donor. A preconditioning regimen of plasmapheresis (PP) and low-dose CMV hyperimmune globulin (CMVIg) was delivered every other day until donor-specific antibody (DSA) titers were reduced to a safe level and isoagglutinin titers were < or =16. Each patient received quadruple sequential immunosuppression, splenectomy and three protocol post-transplant PP/CMVIg treatments. There was no hyperacute rejection. Two of the three patients had a persistent positive cytotoxic crossmatch on the day of transplant and eliminated their DSA subsequently. Antibody-mediated rejection (AMR) in one patient was reversed by reinitiating PP/CMVIg and anti-CD20. The patients are more than 9 months post-transplant with excellent graft function. Preconditioning with PP/CMVIg results in a durable suppression of DSA and permits accommodation of the allograft to a discordant blood type. The ability to cross these two barriers simultaneously is clinically important as sensitized patients have often exhausted their blood type compatible living donors during previous transplants.
Предметные рубрики MeSH
ABO Blood-Group SystemAdultAntibodiesAntigens, CD20Blood Group IncompatibilityBlood Grouping and CrossmatchingFemaleGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunohistochemistryImmunosuppressive AgentsKidneyKidney Failure, ChronicKidney TransplantationKineticsLiving DonorsPlasmapheresisTime Factors